Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is associated with bone loss, erosions, and osteoporosis \[[@CR1]--[@CR3]\]. Several studies suggest that both erosive RA and osteoporosis share a common cellular pathway, which involves inflammatory activation of osteoclasts and decreased osteoblast activation \[[@CR4], [@CR5]\]. Low bone mineral density (BMD) in patients with RA increases the risk of fractures and overall mortality, especially in postmenopausal women \[[@CR6]--[@CR8]\]. Hand BMD loss, as measured by digital X-ray radiogrammetry (DXR)---a sensitive quantitative method for detecting early bone loss by measuring the cortical bone of metacarpal diaphysis---is an independent predictor of radiographic joint damage progression, including erosions \[[@CR9]--[@CR11]\].

A comparison of DXR and dual-energy X-ray absorptiometry (DXA) revealed that DXR appears to be more sensitive than DXA in detecting early bone loss in patients with RA \[[@CR9]\]. Several studies have demonstrated a treatment effect of conventional and biologic disease-modifying antirheumatic drugs (bDMARDs) on BMD loss using DXR \[[@CR4], [@CR12]--[@CR17]\]; however, data are limited on identifying factors that are associated with BMD loss. Given the correlation of DXR--BMD with increased fracture risk and mortality \[[@CR7], [@CR8]\], it would be beneficial to identify a reliable prognostic factor that is associated with hand BMD loss and treatment outcomes in patients with RA. The identification of such prognostic factors could assist rheumatologists in identifying patients at risk of radiographic progression and inform treatment decisions, with the aim of preventing bone erosion.

Anti-citrullinated protein antibody (ACPA) positivity is associated with poor prognosis in RA, and testing for ACPA has become standard practice in the diagnosis of RA \[[@CR18], [@CR19]\]. Recent studies have suggested that ACPA can stimulate bone loss by inducing the differentiation of precursors into bone-resorbing osteoclasts \[[@CR20], [@CR21]\]. In patients who are positive for anti-cyclic citrullinated peptide-2 (anti-CCP2, a surrogate of ACPA) antibodies, structural bone damage can start before the clinical onset of RA \[[@CR22]\]. Elevated anti-CCP2 antibody levels have been found to be independent predictors of localized hand DXR--BMD loss in patients with early RA \[[@CR23]\]. Furthermore, analysis of data from the Pavia Early Arthritis Clinic, a single-center cohort of patients, showed that anti-CCP2 antibodies and rheumatoid factor were associated with systemic bone loss in patients with early, untreated RA \[[@CR24]\]. However, the relationship between hand BMD loss and anti-CCP2 antibodies in patients with established RA is unclear. Data from a recent single-center population study using DXA--BMD showed a negative, titer-dependent effect of ACPA on systemic bone mass at femoral sites in patients with established RA \[[@CR5]\]. This analysis was performed to assess the association between hand DXR--BMD and anti-CCP2 antibody status, DXR--BMD and anti-CCP2 titer, as well as DXR--BMD and RA disease activity among patients with established RA.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

The Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS; ClinicalTrials.gov identifier NCT01793103) registry was initiated in 2003. Details regarding the design of the registry have been reported previously \[[@CR25]--[@CR27]\]. BRASS is a single-center, prospective, observational, longitudinal cohort of more than 1400 adults with established or recent-onset RA who are being followed in a hospital-based practice of 21 rheumatologists in Boston, Massachusetts. The BRASS Registry has been conducted in accordance with International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, applicable regulatory requirements, and ethical tenets originating in the Declaration of Helsinki. The study protocol and informed consent document were reviewed and approved by the Brigham and Women's Hospital Institutional Review Board (approval number 2002P001763). All patients provided written informed consent before participating in the BRASS Registry. The present study population represents a subset of the BRASS cohort, and eligible patients had DXR--BMD and anti-CCP2 antibody measurements at the same time point or within 6 months.

Measures and Data Collection {#Sec14}
----------------------------

Patient demographic data and clinical characteristics, disease activity, and laboratory parameters were assessed at baseline and annually thereafter. Digitized hand radiographs were collected at baseline and at 2, 5, 7, 10, and 12 years and will be collected to at least 15 years (Fig. [1](#Fig1){ref-type="fig"}). Hand BMD was measured at the metacarpal bones of the second, third, and fourth digits using DXR--BMD (DXR-online, Sectra Imtec AB, Linköping, Sweden) as described previously \[[@CR28]\]. Anti-CCP2 antibody level was measured using a validated ELISA (Inova Diagnostics, San Diego, California, USA until its discontinuation in 2011; thereafter Euro-Diagnostica \[distributed by IBL-America, Minneapolis, Minnesota, USA\]). Patient-reported outcomes were assessed with a follow-up questionnaire every 6 months (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) design

Study Outcomes {#Sec4}
--------------

Patient demographic data and clinical characteristics were reported by anti-CCP2 antibody status (anti-CCP2 positive \[+\] and anti-CCP2 negative \[−\]), and anti-CCP2 antibody titer group (Group \[Gp\] 1--3). Anti-CCP2 antibody status was defined either as anti-CCP2+ (≥ 20 U/mL) or anti-CCP2− (\< 20 U/mL). Anti-CCP2+ patients were divided equally into three subgroups based on the tertiles of anti-CCP2 antibody titers as Gp1, 20--96.6 U/mL; Gp2, 96.7--309.6 U/mL, and Gp3, 309.7--580 U/mL. Mean DXR--BMD was reported by anti-CCP2 antibody status and titer groups. The association between Disease Activity Score in 28 joints (DAS28) (C-reactive protein \[CRP\]) \< 2.6 and bone loss was analyzed in patients with DXR--BMD \< 0.5 g/cm^2^ (left or right hand) vs. ≥ 0.5 g/cm^2^ (both hands).

Statistical Analysis {#Sec5}
--------------------

A cross-sectional analysis was performed on available data for DXR--BMD and anti-CCP2 antibody level measured within 6 months of the DXR--BMD measurement. For descriptive statistics, Wilcoxon rank-sum test (or Kruskal--Wallis test) was used for continuous variables and Pearson's Chi-square test for categorical variables. Associations between DXR--BMD (left, right, and combined \[average of left and right hands\]) and anti-CCP2 antibody status and titer (Gp1--3) were explored in multivariate analyses using linear regression controlling for covariates of age, duration of RA, body mass index (BMI), DAS28 (CRP), smoking status, use of steroids, bDMARDs, and osteoporosis medication. With DXR--BMD as the dependent variable, we explored anti-CCP2 antibody level as a continuous variable (linear trend) in relation to DXR--BMD, and explored anti-CCP2 antibody status as a categorical variable and included different anti-CCP2 antibody groups as reference groups.

Associations between DXR--BMD and DAS28 (CRP) \< 2.6 in patients with DXR--BMD ≥ 0.5 and \< 0.5 g/cm^2^ were explored using a logistic model controlling for covariates of age, duration of RA, BMI, smoking status, use of steroids, bDMARDs, and osteoporosis medication.

Results {#Sec6}
=======

Patient Disposition and Patient Characteristics by Anti-CCP2 Antibody Status and Titer Group {#Sec7}
--------------------------------------------------------------------------------------------

A total of 149 patients (all postmenopausal women) had an anti-CCP2 antibody measurement within 6 months of a DXR--BMD measurement: 47 (31.5%) were anti-CCP2−; 102 (68.5%) were anti-CCP2+. Sample sizes for the left and right hands were similar. Of the 102 patients with anti-CCP2+ status, 34 were included in each titer group (Gp1, Gp2, and Gp3). Patient characteristics by anti-CCP2 antibody status and titer group are shown in Table [1](#Tab1){ref-type="table"}. Age, BMI, DAS28 (CRP), smoking status, use of steroids, bDMARDs, and osteoporosis medication did not differ significantly by anti-CCP2 antibody status (±) or between groups (Table [1](#Tab1){ref-type="table"}). Mean duration of RA was different between the groups (*P* \< 0.05); a longer duration of RA was also reported in anti-CCP2+ patients vs. anti-CCP2− patients (Table [1](#Tab1){ref-type="table"}; *P* \< 0.05). However, there was no clear pattern of disease duration between anti-CCP2+ titer groups.Table 1Patient characteristics by anti-CCP2 antibody status and titer groupAnti-CCP2− *n* = 47Anti-CCP2+ *n* = 102Anti-CCP2+ Gp1 *n* = 34Anti-CCP2+ Gp2 *n* = 34Anti-CCP2+, Gp3 *n* = 34Overall population *N* = 149Anti-CCP2 antibody range, U/mL3.0--15.420.0--58020.0--96.696.7--309.6309.7--5803--580Anti-CCP2 antibody level, U/mL, mean (SD)5.1 (2.9)\*\*226.4 (157.0)\*\*55.2 (21.4)\*\*208.1 (61.4)\*\*415.7 (61.2)\*\*156.6 (165.7)Age, years, mean (SD)60.3 (8.4)61.9 (9.6)60.4 (9.0)62.0 (9.5)63.4 (10.3)61.4 (9.3)RA duration, years, mean (SD)12.2 (12.0)\*16.7 (10.8)\*18.0 (11.3)\*15.1 (8.7)\*17.0 (12.1)\*15.3 (11.3)BMI, kg/m^2^, mean (SD)27.3 (5.8)26.9 (5.9)26.0 (4.8)25.6 (4.9)29.2 (7.1)27.0 (5.9)DAS28 (CRP), mean (SD)3.5 (1.4)4.0 (1.5)3.9 (1.5)4.0 (1.6)4.1 (1.5)3.8 (1.5)Steroid use, *n* (%) Never10 (21.3)18 (17.6)6 (17.6)6 (17.6)6 (17.6)28 (18.8) 1--6 months12 (25.5)29 (28.4)8 (23.5)13 (38.2)8 (23.5)41 (27.5) \> 6 months25 (53.2)55 (53.9)20 (58.8)15 (44.1)20 (58.8)80 (53.7)Ever/current smoker, *n* (%)23 (48.9)55 (53.9)16 (47.1)19 (55.9)20 (58.8)78 (52.3)Biologic DMARD, *n* (%)20 (42.6)51 (50.0)17 (50.0)19 (55.9)15 (44.1)71 (47.7)Osteoporosis medication, *n* (%)6 (12.8)15 (14.7)6 (17.6)7 (20.6)2 (5.9)21 (14.1)Anti-CCP2 antibody status was defined as either anti-CCP2+ (≥ 20 U/mL) or anti-CCP2− (\< 20 U/mL)*Anti*-*CCP2* anti-cyclic citrullinated peptide-2 antibody, *anti*-*CCP2*− anti-CCP2 antibody negative, *anti-CCP2+* anti-CCP2 antibody positive, *BMI* body mass index, *CRP* C-reactive protein, *DAS28* Disease Activity Score in 28 joints, *DMARD* disease-modifying antirheumatic drug, *Gp* group, *RA* rheumatoid arthritis\**P* \< 0.05; \*\**P* \< 0.001 comparing anti-CCP2-- vs. anti-CCP2+ or between the three anti-CCP2+ groups

DXR--BMD by Anti-CCP2 Antibody Titer Group {#Sec8}
------------------------------------------

In the univariate analysis, DXR--BMD was lower in the anti-CCP2+ group vs. the anti-CCP2− titer groups (Gp1--3 vs. anti-CCP2−: *P* \< 0.0001 for left and right hands). DXR--BMD decreased with increasing anti-CCP2 antibody titer for the left hand (mean \[SD\]; anti-CCP2− group, 0.56 \[0.08\]; Gp1, 0.51 \[0.09\]; Gp2, 0.51 \[0.08\]; Gp3, 0.48 \[0.1\]), and right hand (0.58 \[0.08\]; 0.52 \[0.09\]; 0.52 \[0.08\]; 0.49 \[0.1\], respectively) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Association between DXR--BMD and anti-CCP2 antibody status and titer in **a** left hand and **b** right hand. Number of patients in each titer group: anti-CCP2--, *n* = 47; Gp1, *n* = 34; GP2, *n* = 34; Gp3, *n* = 34. Timeframe between DXR--BMD and anti-CCP2 measurements (months \[SD\]) were 0.6 (1.4) for anti-CCP2--, 1.8 (2.3) for Gp1, 1.1 (1.8) for GP2, and 1.0 (1.7) for Gp3 (*P* \> 0.05 for comparison between the anti-CCP2+ groups and the anti-CCP2-- group).*Anti-CCP2* anti-cyclic citrullinated peptide-2 antibodies,*anti-CCP2--* anti-CCP2 antibody negative,*anti-CCP2+* anti-CCP2 antibody positive,*DXR--BMD* digital X-ray radiogrammetry--bone mineral density,*Gp* group

Associations Between DXR--BMD and Anti-CCP2 Antibody Status: Multivariate Analysis {#Sec9}
----------------------------------------------------------------------------------

When anti-CCP2 antibody level was used as a continuous variable, combined hand DXR--BMD was negatively associated with anti-CCP2. For every 10-unit increase in anti-CCP2 antibody level, DXR--BMD decreased by 0.0014 units (*P* \< 0.001; see Supplementary Table 1). The overall model fit based on adjusted*R*^2^ for the total hand DXR--BMD model was 0.406. When anti-CCP2 antibody status was used as a categorical variable, combined hand DXR--BMD was associated with anti-CCP2+ Gp1--3 vs. anti-CCP2− (*P* \< 0.001; Table [2](#Tab2){ref-type="table"}). Combined hand DXR--BMD was negatively associated with each individual anti-CCP2 antibody titer group (Gp1, Gp2, or Gp3) vs. anti-CCP2− (*P* \< 0.05). Adjusted*R*^2^ for the total hand DXR--BMD model was 0.426. This negative association between DXR--BMD and each individual anti-CCP2 antibody titer group vs. anti-CCP2− remained significant in the multivariate analysis (Table [2](#Tab2){ref-type="table"}).Table 2Exploration of anti-CCP2 antibody status and titer as a categorical variable in relation to DXR--BMDVariableLeft-hand DXR--BMDRight-hand DXR--BMDAverage of left and right handsCoefficient*P* valueAdjusted *P* value^c^Coefficient*P* valueAdjusted *P* value^c^Coefficient*P* valueAdjusted *P* value^c^Anti-CCP2− (vs. anti-CCP2+ Gp1--3)^a^0.0523\< 0.0010.00070.0586\< 0.0010.00010.0568\< 0.0010.0001Anti-CCP2+ Gp1 (vs. anti-CCP2−)^a^−0.04750.0070.029− 0.05550.0020.0089− 0.05420.0020.0097Anti-CCP2+ Gp2 (vs. anti-CCP2−)^a^− 0.03940.0200.0608− 0.04770.0060.0183− 0.04640.0050.0166Anti-CCP2+ Gp3 (vs. anti-CCP2−)^a^− 0.0683\< 0.0010.0005− 0.0715\< 0.0010.0003− 0.0686\< 0.0010.0002Anti-CCP2+ Gp1 (vs. Gp3)^a^0.02080.2680.2680.01610.3950.3950.01440.4420.442Anti-CCP2+ Gp2 (vs. Gp3)^a^0.02890.1130.2260.02380.2010.3950.02210.2150.43Anti-CCP2+ Gp3 (vs. anti-CCP2−, Gp1, and Gp2)^a^−0.04420.0040.0188− 0.04330.0060.0183− 0.04220.0060.0166Age, years− 0.0037\< 0.001--− 0.0036\< 0.001--− 0.0036\< 0.001--RA duration, years− 0.00130.030--− 0.00130.026--− 0.0010.081--BMI, kg/m^2^0.00180.112--0.00210.063--0.00160.148--DAS28 (CRP)− 0.00230.603--− 0.00140.760--− 0.00150.736--Steroid use 1--6 months (vs. never)− 0.02480.174--− 0.00140.940--− 0.00760.664--Steroid use \> 6 months (vs. never)− 0.03580.040--− 0.03240.061--− 0.03460.038--Smoker (ever/current vs. never)− 0.00590.637--− 0.01250.324--− 0.01030.400--Biologic DMARD (yes vs. no)− 0.0130.332--0.01180.378--0.00420.746--Osteoporosis medication (yes vs. no)− 0.04810.008--− 0.04770.009--− 0.04690.008--*R*^2^, adjusted^b^0.399----0.421----0.426----Anti-CCP2 antibody status was defined as either anti-CCP2+ (≥ 20 U/mL) or anti-CCP2− (\< 20 U/mL). Anti-CCP2+ titer groups were defined as Gp1, 20.0--96.6 U/mL; Gp2, 96.7--309.6 U/mL; or Gp3, 309.7--580 U/mL*Anti*-*CCP2* anti-cyclic citrullinated peptide-2 antibody, *anti-CCP2−* anti-CCP antibody negative, *anti*-*CCP2*+ anti-CCP2 antibody positive, *BMI* body mass index, *BMD* bone mineral density, *CRP* C-reactive protein, *DAS28* Disease Activity Score in 28 joints, *DMARD* disease-modifying antirheumatic drug, *DXR* digital X-ray radiogrammetry, *Gp* group, *RA* rheumatoid arthritis^a^Four separate models with different reference groups or comparisons as specified in the table for each of the three outcomes^b^The model included all covariates in the table (age, duration of RA, BMI, smoking status, use of steroids,*bDMARDs* biologic disease-modifying antirheumatic drugs, and osteoporosis medication) and three dummy variables for the three anti-CCP2+ groups (vs. anti-CCP2−)^c^*P* values were adjusted for multiple comparison based on Hochberg's method that controls the familywise error rate under independence \[[@CR29]\]

Results for individual hands were similar to those for the combined analysis (Table [2](#Tab2){ref-type="table"} and Supplementary Table 1). When anti-CCP2 antibody level was used as a continuous variable, for every 10-unit increase in anti-CCP2, DXR--BMD for the left or right hand decreased by 0.0014 units (*P* \< 0.001; see Supplementary Table 1). Similarly, when anti-CCP2 antibody status was used as a categorical variable, left or right hand DXR--BMD was associated with anti-CCP2+ Gp1--Gp3 vs. anti-CCP2− (*P* \< 0.001; Table [2](#Tab2){ref-type="table"}).

DXR--BMD was negatively associated with age, duration of RA, and use of osteoporosis medication. In the model with anti-CCP2 antibody status as a categorical variable, steroid use \> 6 months was also a significant factor for DXR--BMD (left or average; Table [2](#Tab2){ref-type="table"}).

Association Between Disease Activity and Bone Loss {#Sec10}
--------------------------------------------------

Evaluation of the association between DXR--BMD and disease activity indicates that patients with low DXR--BMD were less likely to have a DAS28 (CRP) \< 2.6 (DXR--BMD ≥ 0.5, 36.5% vs. DXR--BMD \< 0.5, 18.8%; *P* = 0.0181) (Fig. [3](#Fig3){ref-type="fig"}). After controlling for confounding factors, the odds of having a DAS28 (CRP) \< 2.6 were significantly lower for patients with DXR--BMD \< 0.5 (*n* = 64) vs. ≥ 0.5 (*n* = 85; odds ratio 0.355 \[95% CI 0.126--0.998\]; *P* = 0.0496).Fig. 3Association between DXR--BMD and DAS28 (CRP) \< 2.6.*CRP* C-reactive protein,*DAS28* Disease Activity in 28 joints,*DXR--BMD* digital X-ray radiogrammetry--bone mineral density

Discussion {#Sec11}
==========

Our results show that, among patients with long-standing RA, hand DXR--BMD is negatively associated with the presence of anti-CCP2 antibodies. Patients with anti-CCP2+ status, particularly those with high anti-CCP2 antibody titers, had lower hand BMD; therefore, as anti-CCP2 antibody titers increased, hand BMD decreased. This is consistent with previous studies in patients with early RA, demonstrating a correlation between elevated anti-CCP2 antibody baseline levels and DXR--BMD loss \[[@CR23], [@CR24]\].

In the present analysis, patients with low DXR--BMD were less likely to have low disease activity. Similar observations have also been reported in patients with early RA \[[@CR30]\], suggesting an association between disease activity and bone loss. Hand BMD loss has also been shown to indicate an increased risk of erosive disease \[[@CR10], [@CR11], [@CR31], [@CR32]\]. Data from an observational study demonstrated that BMD loss at 6 months was associated with higher erosion scores, and a higher proportion of patients with BMD loss at 6 months had at least one erosion and a higher risk of erosion progression at 12 months \[[@CR31]\]. Furthermore, although there is evidence that hand joint damage in RA is related to use and hand dominance \[[@CR33]\], our data show that bone loss occurs in both hands, which is consistent with RA being defined as a symmetrical disease. Such patients with low hand BMD may be at an increased risk of vertebral and non-vertebral fractures \[[@CR6], [@CR7]\].

Pro-inflammatory cytokines are generally the key drivers of articular and extra-articular bone damage \[[@CR34]--[@CR36]\]. However, recent evidence has shown that RA-associated autoantibodies, such as ACPA, can directly induce bone loss by stimulating osteoclast differentiation \[[@CR20], [@CR21]\]. In vivo, human ACPA causes bone loss in immune-deficient mice \[[@CR20]\]. ACPA has been shown to be associated with bone loss as demonstrated through DXR--BMD in this study as well as DXA--BMD in a separate study \[[@CR24]\]. Patients with ACPA develop cortical thinning, leading to a decrease in bone mass and increasing the risk of bone erosions \[[@CR3], [@CR22]\]. Given the evidence suggesting that ACPA is a key driver of bone loss \[[@CR23], [@CR24]\], treatment options for RA that reduce ACPA titers and induce seroconversion may be effective in lowering the risk of bone loss. This should be explored in future clinical trials.

The strength of this analysis is that these data are from an observational cohort of patients with RA, including clinical measures such as serological status and DXR--BMD. Limitations of this analysis include those inherent in observational cross-sectional studies, including the absence of a comparator (e.g., DXR--BMD in healthy, postmenopausal women) and hand radiographs and ACPA testing may not have been done on the same day. Even though our statistical models controlled for several covariates and observed significant relationships between DXR--BMD and ACPA or disease activity, this does not imply causation or rule out certain biases without further controlled analyses. Confounding by unmeasured variables should also be considered when evaluating these results. The selection of \< 0.5 as compared with ≥ 0.5 g/cm^2^ in relation to DAS28 (CRP) \< 2.6 should also be considered as a potential limitation. However, the cutoff was selected in reference to the DXR--BMD median of Gp3 and needs further validation in future studies. In addition, antibodies to individual citrullinated proteins (e.g. fibrin, filaggrin, vimentin) or other serological markers (e.g., rheumatoid factor) were not evaluated. The patient population primarily reflects postmenopausal women; therefore, future studies should be conducted in pre- and postmenopausal women as these results may have implications for osteoporosis prevention.

Conclusions {#Sec12}
===========

Our results show that, in routine clinical practice, anti-CCP2 antibody positivity in patients with established RA is associated with lower hand BMD, and patients with hand bone loss were less likely to have low disease activity. This suggests that DXR--BMD and anti-CCP2 antibody status could help identify patients at risk for joint progression and fracture; however, a direct causal relationship cannot necessarily be implied from this cross-sectional analysis. Disease-modifying treatment for RA that not only targets inflammation but improves cortical bone density should be considered in order to achieve better prevention of bone erosions in patients with RA.
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